A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.

Brigandi, Richard A; Johnson, Brendan; Oei, Coreen; Westerman, Mark; Olbina, Gordana; de Zoysa, Janak; Roger, Simon D; Sahay, Manisha; Cross, Nicholas; McMahon, Lawrence; Guptha, Veerabhadra; Smolyarchuk, Elena A; Singh, Narinder; Russ, Steven F; Kumar, Sanjay

Brigandi, Richard A; Johnson, Brendan; Oei, Coreen; Westerman, Mark; Olbina, Gordana; de Zoysa, Janak; Roger, Simon D; Sahay, Manisha; Cross, Nicholas; McMahon, Lawrence; Guptha, Veerabhadra; Smolyarchuk, Elena A; Singh, Narinder; Russ, Steven F; Kumar, Sanjay.

Afiliação

Brigandi RA; Virtual Proof of Concept Discovery Performance Unit, GlaxoSmithKline, King of Prussia, PA. Electronic address: richard.a.brigandi@gsk.com.
Johnson B; Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, Research Triangle Park, NC.
Oei C; Virtual Proof of Concept Discovery Performance Unit, GlaxoSmithKline, King of Prussia, PA.
Westerman M; Intrinsic LifeSciences, La Jolla, CA.
Olbina G; Intrinsic LifeSciences, La Jolla, CA.
de Zoysa J; North Shore Hospital, Waitemata District Health Board, Auckland, New Zealand.
Roger SD; Renal Research, Gosford, Australia.
Sahay M; Osmania General Hospital, Hyderabad, India.
Cross N; Department of Nephrology, Christchurch Hospital.
McMahon L; Monash University, Melbourne, Australia.
Guptha V; Rangadore Memorial Hospital, Bangalore, India.
Smolyarchuk EA; Moscow State University of Medicine & Dentistry, Moscow, Russia.
Singh N; Pushpanjali Crosslay Hospital, Uttar Pradesh, India.
Russ SF; Virtual Proof of Concept Discovery Performance Unit, GlaxoSmithKline, King of Prussia, PA.
Kumar S; Virtual Proof of Concept Discovery Performance Unit, GlaxoSmithKline, King of Prussia, PA.

Am J Kidney Dis ; 67(6): 861-71, 2016 Jun.

Article em En | MEDLINE | ID: mdl-26827289

Assuntos

Anemia/tratamento farmacológico; Anemia/etiologia; Barbitúricos/uso terapêutico; Glicina/análogos & derivados; Prolina Dioxigenases do Fator Induzível por Hipóxia/antagonistas & inibidores; Inibidores de Prolil-Hidrolase/uso terapêutico; Insuficiência Renal Crônica/complicações; Adolescente; Adulto; Idoso; Idoso de 80 Anos ou mais; Feminino; Glicina/uso terapêutico; Humanos; Masculino; Pessoa de Meia-Idade; Método Simples-Cego; Fatores de Tempo; Adulto Jovem

Palavras-chave

Erythropoietin (EPO); chronic kidney disease (CKD); dialysis; dosing; erythropoiesis-stimulating agent (ESA); hemoglobin; hemoglobin response rate; hepcidin; hypoxia-inducible factor (HIF); pharmacodynamics; pharmacokinetics; phase II; prolyl hydroxylase inhibitor (PHI); randomized controlled trial (RCT); reticulocyte count

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Barbitúricos / Insuficiência Renal Crônica / Prolina Dioxigenases do Fator Induzível por Hipóxia / Inibidores de Prolil-Hidrolase / Glicina / Anemia Tipo de estudo: Clinical_trials / Guideline Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Kidney Dis Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google